6580 Share Price Performance
NT$13.05
-11.95 (-47.80%)
Price NT$13.05
Share Pricen/a
TaiRx, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
6580 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
TaiRx, Inc. Key Details
About 6580
- Founded
- 2011
- Employees
- n/a
- CEO
- WebsiteView website
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs for the use in cancer therapy. TaiRx, Inc. was founded in 2011 and is based in Taipei, Taiwan.
